U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C12H16N2
Molecular Weight 188.2688
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of IPIDACRINE

SMILES

NC1=C2CCCCC2=NC3=C1CCC3

InChI

InChIKey=YLUSMKAJIQOXPV-UHFFFAOYSA-N
InChI=1S/C12H16N2/c13-12-8-4-1-2-6-10(8)14-11-7-3-5-9(11)12/h1-7H2,(H2,13,14)

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including http://onlinelibrary.wiley.com/doi/10.1111/j.1527-3458.1998.tb00067.x/pdf

Ipidacrine (Neiromidin) is a drug first synthesized by the National Research Center for Biologically Active Compounds in the Russian Federation. Neuromidin has a direct stimulating effect on the conduct of the pulse along the nerve fibers, interneuronal and neuromuscular synapses of the CNS and peripheral nervous system. Pharmacological action neuromidin is based on a combination of two mechanisms of action: blockade of potassium channels of the membrane of neurons and muscle cells; reversible inhibition of cholinesterase in synapses. Neuromidin enhances the effect on smooth muscle acetylcholine not only, but epinephrine, serotonin, histamine and oxytocin. It has the following pharmacological effects: - Improve and stimulate impulse conduction in the nervous system and neuromuscular transmission; - Enhances contractility of smooth muscle organs under the influence of acetylcholine agonists, adrenaline, serotonin, histamine and oxytocin receptors, with the exception of potassium chloride; - Improves memory, slows progressive course of dementia. In preclinical studies Neuromidin is not teratogenic, embryotoxic, mutagenic, carcinogenic and immunotoxic action, had no effect on the endocrine system

CNS Activity

Curator's Comment: Neuromidin (ipidacrine) has a direct stimulating effect on the conduct of the pulse along the nerve fibers, interneuronal and neuromuscular synapses of the CNS and peripheral nervous system.

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Neuromidin

Approved Use

Unknown
Primary
Neuromidin

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Antiamnesic and cholinomimetic side-effects of the cholinesterase inhibitors, physostigmine, tacrine and NIK-247 in rats.
1993 Nov 30
Effects of NIK-247 on cholinesterase and scopolamine-induced amnesia.
1997 May
Patents

Patents

Sample Use Guides

Dose and duration of treatment is determined individually depending on the severity of the disease. Peripheral nervous system diseases: 10-20 mg; 1-3 times a day. The treatment is 1 to 2 months. To prevent myasthenic crises, severe violations of neuromuscular conduction briefly parenterally administered 1-2 ml (15-30 mg) Neuromidin 1,5% solution for injection, and then continue treatment tablets Neuromidin, the dose can be increased to 20-40 mg; 5 times a day.
Route of Administration: Other
In Vitro Use Guide
Unknown
Name Type Language
IPIDACRINE
INN   MART.   MI   WHO-DD  
INN  
Official Name English
ipidacrine [INN]
Common Name English
9-AMINO-2,3,5,6,7,8-HEXAHYDRO-1H-CYCLOPENTA(B)QUINOLINE
Systematic Name English
IPIDACRINE [MART.]
Common Name English
Ipidacrine [WHO-DD]
Common Name English
IPIDACRINE [MI]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C66880
Created by admin on Sat Dec 16 15:55:50 GMT 2023 , Edited by admin on Sat Dec 16 15:55:50 GMT 2023
WHO-VATC QN06DA05
Created by admin on Sat Dec 16 15:55:50 GMT 2023 , Edited by admin on Sat Dec 16 15:55:50 GMT 2023
WHO-ATC N06DA05
Created by admin on Sat Dec 16 15:55:50 GMT 2023 , Edited by admin on Sat Dec 16 15:55:50 GMT 2023
Code System Code Type Description
MERCK INDEX
m776
Created by admin on Sat Dec 16 15:55:50 GMT 2023 , Edited by admin on Sat Dec 16 15:55:50 GMT 2023
PRIMARY Merck Index
FDA UNII
CV71VTP0VN
Created by admin on Sat Dec 16 15:55:50 GMT 2023 , Edited by admin on Sat Dec 16 15:55:50 GMT 2023
PRIMARY
EVMPD
SUB08273MIG
Created by admin on Sat Dec 16 15:55:50 GMT 2023 , Edited by admin on Sat Dec 16 15:55:50 GMT 2023
PRIMARY
NCI_THESAURUS
C65952
Created by admin on Sat Dec 16 15:55:50 GMT 2023 , Edited by admin on Sat Dec 16 15:55:50 GMT 2023
PRIMARY
DRUG BANK
DB13668
Created by admin on Sat Dec 16 15:55:50 GMT 2023 , Edited by admin on Sat Dec 16 15:55:50 GMT 2023
PRIMARY
SMS_ID
100000083140
Created by admin on Sat Dec 16 15:55:50 GMT 2023 , Edited by admin on Sat Dec 16 15:55:50 GMT 2023
PRIMARY
EPA CompTox
DTXSID7048299
Created by admin on Sat Dec 16 15:55:50 GMT 2023 , Edited by admin on Sat Dec 16 15:55:50 GMT 2023
PRIMARY
MESH
C049860
Created by admin on Sat Dec 16 15:55:50 GMT 2023 , Edited by admin on Sat Dec 16 15:55:50 GMT 2023
PRIMARY
INN
7385
Created by admin on Sat Dec 16 15:55:50 GMT 2023 , Edited by admin on Sat Dec 16 15:55:50 GMT 2023
PRIMARY
DRUG CENTRAL
4808
Created by admin on Sat Dec 16 15:55:50 GMT 2023 , Edited by admin on Sat Dec 16 15:55:50 GMT 2023
PRIMARY
PUBCHEM
604519
Created by admin on Sat Dec 16 15:55:50 GMT 2023 , Edited by admin on Sat Dec 16 15:55:50 GMT 2023
PRIMARY
CAS
62732-44-9
Created by admin on Sat Dec 16 15:55:50 GMT 2023 , Edited by admin on Sat Dec 16 15:55:50 GMT 2023
PRIMARY
ChEMBL
CHEMBL130880
Created by admin on Sat Dec 16 15:55:50 GMT 2023 , Edited by admin on Sat Dec 16 15:55:50 GMT 2023
PRIMARY
WIKIPEDIA
Ipidacrine
Created by admin on Sat Dec 16 15:55:50 GMT 2023 , Edited by admin on Sat Dec 16 15:55:50 GMT 2023
PRIMARY